{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:55Z","timestamp":1790674135383,"version":"4.1.0"},"reference-count":62,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.15756","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T15:36:56Z","timestamp":1599147416000},"page":"e2015756","source":"Crossref","is-referenced-by-count":33,"title":["Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States"],"prefix":"10.1001","volume":"3","author":[{"given":"Moosa","family":"Tatar","sequence":"first","affiliation":[{"name":"Matheson Center for Health Care Studies, the University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana W.","family":"Keeshin","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, the University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mailliard","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center College of Medicine, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando A.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Matheson Center for Health Care Studies, the University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"issue":"34","key":"zoi200587r1","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes.","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"zoi200587r2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/j.gastro.2006.06.007","article-title":"Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States.","volume":"131","author":"Nainan","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"zoi200587r4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/003335490612100611","article-title":"Self-reported hepatitis C virus antibody status and risk behavior in young injectors.","volume":"121","author":"Hagan","year":"2006","journal-title":"Public Health Rep"},{"issue":"4","key":"zoi200587r6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"7053","key":"zoi200587r7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation.","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"issue":"10","key":"zoi200587r8","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes.","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"zoi200587r9","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C.","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"issue":"8","key":"zoi200587r10","doi-asserted-by":"publisher","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016.","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi200587r11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003-2013.","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi200587r12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"zoi200587r13","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1086\/590167","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.","volume":"46","author":"Amon","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi200587r15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/499960","article-title":"Injection drug users: the overlooked core of the hepatitis C epidemic.","volume":"42","author":"Edlin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi200587r16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2105\/AJPH.2013.301601","article-title":"Estimating acute viral hepatitis infections from nationally reported cases.","volume":"104","author":"Klevens","year":"2014","journal-title":"Am J Public Health"},{"issue":"4","key":"zoi200587r17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi200587r18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097596","article-title":"Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.","volume":"9","author":"Lansky","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"zoi200587r19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.7326\/0003-4819-144-10-200605160-00010","article-title":"A framework for management of hepatitis C in prisons.","volume":"144","author":"Spaulding","year":"2006","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi200587r20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.","volume":"129","author":"Varan","year":"2014","journal-title":"Public Health Rep"},{"issue":"5","key":"zoi200587r21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States.","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"issue":"12","key":"zoi200587r22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jama.2012.374","article-title":"Screening for HCV infection in jails.","volume":"307","author":"Spaulding","year":"2012","journal-title":"JAMA"},{"issue":"20","key":"zoi200587r23","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1056\/NEJMp1311941","article-title":"Responding to hepatitis C through the criminal justice system.","volume":"370","author":"Rich","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi200587r24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2105\/AJPH.94.7.1218","article-title":"Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.","volume":"94","author":"Macalino","year":"2004","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi200587r25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1377\/hlthaff.2013.1133","article-title":"How health care reform can transform the health of criminal justice-involved individuals.","volume":"33","author":"Rich","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"zoi200587r27","first-page":"501","article-title":"Safety and economic evaluation of patients treated for hepatitis with antiviral daclatasvir and sofosbuvir combined vs ledipasvir\/sofosbuvir 90mg\/400mg in a medical institution in the UAE.","volume":"10","author":"Alomar","year":"2018","journal-title":"J of Pharm Sci and Res"},{"issue":"1","key":"zoi200587r28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/pubmed\/fdh109","article-title":"Screening for hepatitis C in injecting drug users: a cost utility analysis.","volume":"26","author":"Stein","year":"2004","journal-title":"J Public Health (Oxf)"},{"issue":"3","key":"zoi200587r29","doi-asserted-by":"publisher","first-page":"E110","DOI":"10.1503\/cmaj.140711","article-title":"Cost-effectiveness of screening for hepatitis C in Canada.","volume":"187","author":"Wong","year":"2015","journal-title":"CMAJ"},{"issue":"1","key":"zoi200587r30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.215.33","article-title":"Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.","volume":"215","author":"Nakamura","year":"2008","journal-title":"Tohoku J Exp Med"},{"issue":"10","key":"zoi200587r31","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/cid\/cit069","article-title":"Cost-effectiveness of screening for chronic hepatitis C infection in the United States.","volume":"56","author":"Eckman","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi200587r32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings.","volume":"156","author":"Rein","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi200587r33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ajog.2004.10.600","article-title":"Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.","volume":"192","author":"Plunkett","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"zoi200587r34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0002-9343(01)00951-2","article-title":"Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.","volume":"111","author":"Singer","year":"2001","journal-title":"Am J Med"},{"issue":"1","key":"zoi200587r35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/vox.2004.86.issue-1","article-title":"Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.","volume":"86","author":"Marshall","year":"2004","journal-title":"Vox Sang"},{"issue":"2","key":"zoi200587r36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0266462313000160","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement.","volume":"29","author":"Husereau","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"zoi200587r37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.","volume":"290","author":"Salomon","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"zoi200587r38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026783","article-title":"Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"zoi200587r39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi200587r40","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.18632\/oncotarget.v8i1","article-title":"Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China.","volume":"8","author":"Liao","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"zoi200587r41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2013.11.016","article-title":"Staging chronic hepatitis C in seven categories using fibrosis biomarker and transient elastography.","volume":"60","author":"Poynard","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"zoi200587r42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0168-8278(02)00357-4","article-title":"Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems.","volume":"38","author":"Rozario","year":"2003","journal-title":"J Hepatol"},{"issue":"8","key":"zoi200587r44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13696998.2016.1176030","article-title":"Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.","volume":"19","author":"Saab","year":"2016","journal-title":"J Med Econ"},{"issue":"3","key":"zoi200587r45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s12072-008-9086-x","article-title":"Demographics of a large cohort of urban chronic hepatitis C patients.","volume":"2","author":"Siddiqui","year":"2008","journal-title":"Hepatol Int"},{"issue":"3","key":"zoi200587r46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12072-018-9873-y","article-title":"Glecaprevir\/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.","volume":"12","author":"Abutaleb","year":"2018","journal-title":"Hepatol Int"},{"issue":"18","key":"zoi200587r47","article-title":"Glecaprevir and Pibrentasvir Tablets (Mavyret).","volume":"39","author":"Elliott","year":"2017","journal-title":"Intern Med Alert"},{"issue":"7","key":"zoi200587r48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.","volume":"17","author":"McAdam-Marx","year":"2011","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"zoi200587r50","first-page":"12","article-title":"HCV testing cost-effective alternative to treating advanced disease.","volume":"2","author":"Carlson","year":"2005","journal-title":"Biotechnol Healthc"},{"issue":"16","key":"zoi200587r52","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses.","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"zoi200587r54","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.v69.3","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"14","key":"zoi200587r55","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn\u2019t it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"issue":"1","key":"zoi200587r56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1017\/S0950268811000112","article-title":"Cost-effectiveness of targeted screening for hepatitis C in the Netherlands.","volume":"140","author":"Helsper","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"9","key":"zoi200587r57","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/cid\/cis011","article-title":"Cost-effectiveness and population outcomes of general population screening for hepatitis C.","volume":"54","author":"Coffin","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi200587r58","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cgh.2018.08.080","article-title":"Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens.","volume":"17","author":"Eckman","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi200587r59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.drugalcdep.2018.07.034","article-title":"Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: protective effects of non-injecting drug use.","volume":"192","author":"Des Jarlais","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi200587r60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response.","volume":"64","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"zoi200587r61","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2017.06.013","article-title":"A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses.","volume":"21","author":"Levy","year":"2018","journal-title":"Value Health"},{"key":"zoi200587r3","volume-title":"Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C.","author":"Mitchell","year":"2010"},{"key":"zoi200587r53","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Weinstein","year":"1996"},{"key":"zoi200587r5","unstructured":"US Centers for Disease Control and Prevention. Hepatits C. Published 2019. Accessed November 6, 2019. https:\/\/www.cdc.gov\/hepatitis\/hcv\/index.htm?"},{"key":"zoi200587r14","unstructured":"US Centers for Disease Control and Prevention. Surveillance Data for Viral Hepatitis. Published 2016. Accessed June 4, 2020. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2016surveillance\/commentary.htm"},{"key":"zoi200587r26","unstructured":"Neate? R. Welcome to Jail Inc: how private companies make money off US prisons.? The Guardian. June 16, 2016. Accessed July 20. 2020. https:\/\/www.theguardian.com\/us-news\/2016\/jun\/16\/us-prisons-jail-private-healthcare-companies-profit"},{"key":"#cr-split#-zoi200587r43.1","unstructured":"Arias? E, Xu? J.? United States life tables, 2017. National Vital Statistics Reports, 68(7). US Department of Health and Human Services"},{"key":"#cr-split#-zoi200587r43.2","unstructured":"2019. Accessed July 23, 2020. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_07-508.pdf"},{"key":"zoi200587r49","unstructured":"Bentley? TS, Philips? JS, Hanson? SG. 2017 US organ and tissue transplant cost estimates and discussion. Milliman Research Report; 2017. Accessed July 20, 2020. https:\/\/milliman-cdn.azureedge.net\/-\/media\/milliman\/importedfiles\/uploadedfiles\/insight\/2017\/2017-transplant-report.ashx"},{"key":"zoi200587r51","unstructured":"US Department of Labor Bureau of Labor Statistics. Consumer Price Index. Published 2019. Accessed November 13, 2019. https:\/\/data.bls.gov\/cgi-bin\/cpicalc.pl?cost1=104.00&year1=200501&year2=201910"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2770156\/tatar_2020_oi_200587_1602709414.06639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T20:29:21Z","timestamp":1617136161000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2770156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15756","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}